ライフサイエンスコーパス: amifostine

1 ted in the presence of the antioxidant agent amifostine.

2 oprotector to become available clinically is amifostine.

3 ioxide emission in cancer patients receiving amifostine.

4 ding the activity of dexrazoxane, mesna, and amifostine.

5 Median saliva production was greater with amifostine (0.26 g v 0.10 g, P=.04).

6 Amifostine: (1) Amifostine may be considered for the red

7 Mice received once-daily dosing with amifostine (10-100 mg/kg, intraperitoneal injection) 3 d

8 To evaluate the hematological effects of amifostine, 18 patients with myelodysplastic syndrome (M

9 With and without amifostine, 2-year local-regional control, disease-free

10 xrazoxane, three reports (two studies) each; amifostine, 33 reports (31 studies); and mesna, no publi

11 Following chemotherapy, patients received amifostine (340 mg/m2 4 days a week for 5 weeks, or 200

12 When used, amifostine (600 mg/m(2)/dose) was administered as a bolu

13 aclitaxel 175 mg/m2 over 3 hours followed by amifostine 740 mg/m2 and cisplatin 75 mg/m2 administered

14 Patients received amifostine (740 or 910 mg/m2) followed by cisplatin (120

15 2) and cisplatin (100 mg/m2) with or without amifostine (910 mg/m2) every 3 weeks for six cycles.

16 We conclude that amifostine administered at doses </=200 mg/m2 three time

17 Amifostine administered before and during the cisplatin

18 This study tested effects of chronic amifostine administration on parameters of oxidative str

19 d over 90 minutes beginning 15 minutes after amifostine administration.

20 ts were randomly assigned at registration to amifostine (AM) 500 mg IV four times per week or no AM d

21 Patients were randomly assigned to amifostine (AM) or no AM during chemoradiotherapy.

22 Amifostine, an organic thiophosphate, has demonstrated t

23 athologic tumor response rates were 37% with amifostine and 28% in controls, with comparable median s

24 In agreement, amifostine and WR-1065 coincubation reduced uptake in BN

25 -protectant activity-dexrazoxane, mesna, and amifostine-and questions about the role of these protect

26 Amifostine appears to reduce cisplatin-related nephrotox

27 Amifostine attenuates oxidative stress and improves lipo

28 Pretreatment with amifostine before each cycle of chemotherapy resulted in

29 Amifostine can be administered safely with high-dose cis

30 oxic drugs, we conducted a phase II trial of amifostine, cisplatin, and vinblastine (ACV) in patients

31 CA20948 tumor-bearing rats, with or without amifostine coadministration, via several routes.

32 ography-mass spectrometry confirmed that the amifostine conversion to WR-1065 was significantly more

33 This randomized trial evaluated whether amifostine could ameliorate these side effects without c

34 This study was designed to determine if amifostine could reduce the serious toxicities associate

35 findings shed new light on the mechanism of amifostine cytoprotection and encourage clinical researc

36 Coadministration of amifostine decreased renal uptake of radiolabeled octreo

37 Amifostine did not reduce mucositis.

38 Amifostine doses less than or equal to 200 mg/m2 were we

39 e, David Brizel, who worked on the phase III amifostine efficacy study, and Jens Overgaard, a vehemen

40 The aminothiol, amifostine (Ethyol; U.S. Bioscience, West Conshohocken,

41 ifty-three percent of the patients receiving amifostine had at least one episode of nausea and/or vom

42 e and survival data provide no evidence that amifostine impairs response to treatment.

43 efractory cytopenias received treatment with amifostine in a Phase I/II study.

44 lines for the use of dexrazoxane, mesna, and amifostine in patients who are not enrolled on clinical

45 Although amifostine in vitro did not inhibit the activity of the

46 patients (16%) required early stopping of an amifostine infusion due to hypotension.

47 Amifostine is the prototype drug.

48 Amifostine may be considered for prevention of cisplatin

49 Amifostine: (1) Amifostine may be considered for the reduction of nephro

50 amifostine to its active metabolite WR-1065, amifostine may not only protect in multiple ways normal

51 clinical and clinical studies that suggested amifostine may potentiate the effects of cytotoxic drugs

52 nerally reversible and the data suggest that amifostine may protect against long-term renal insuffici

53 Amifostine may provide renal protection during PRRT usin

54 The effects of amifostine on human basal metabolism, mouse liver metabo

55 This study describes the direct effect of amifostine on kidney and tumor uptake of (111)In-DOTA,Ty

56 Moreover, amifostine opponents argue that the evidence is insuffic

57 g BN-16 cells, in the absence or presence of amifostine or its active metabolite WR-1065.

58 r percent of CP patients compared with 9% of amifostine plus CP patients discontinued therapy because

59 Amifostine preconditioning activates lung tissue antioxi

60 mg/m2) was given weekly for 5 weeks with no amifostine pretreatment.

61 Amifostine prevented the development of MMC-induced PVOD

62 Amifostine prevents MMC-induced PVOD in rats and should

63 In vitro, amifostine promotes the formation and survival of primit

64 The cytoprotective agent amifostine protected rats from long-term nephrotoxicity

65 Amifostine protects normal cells from DNA damage inducti

66 Amifostine reduced acute and chronic xerostomia.

67 Amifostine reduced grade > or =2 acute xerostomia from 7

68 Pretreatment with amifostine reduces the cumulative hematologic, renal, an

69 Preincubation with amifostine reversed the high-glucose effects.

70 Amifostine's level of activity in this trial was insuffi

71 Amifostine selectively protects NCTC cells against radia

72 at the thiol form of the cytoprotective drug amifostine that is designated WR-1065 [2-((aminopropyl)a

73 , and Jens Overgaard, a vehement opponent of amifostine therapy, provide thought-provoking arguments

74 venous treatment with 100, 200, or 400 mg/m2 amifostine three times a week, or 740 mg/m2 weekly for t

75 d cancer cells in their abilities to convert amifostine to its active metabolite WR-1065, amifostine

76 r response, some institutions are now adding amifostine to their chemoradiation regimens.

77 4.5%; one-sided chi(2) test P = .005) of the amifostine-treated patients had at least grade 3 ototoxi

78 r increase in absolute neutrophil count with amifostine treatment (range, 426 to 11,348/microL).

79 solution immunofluorescence microscopy) that amifostine treatment supports DSB repair in gamma-irradi

80 Amifostine was administered (200 mg/m(2) intravenous) da

81 Amifostine was administered intravenously 3 times a week

82 Amifostine was generally well tolerated; the principal s

83 Amifostine was well-tolerated.

84 These protective effects of amifostine were associated with increased superoxide dis

85 n patients with AR medulloblastoma (n = 62), amifostine would decrease the need for hearing aids (def

86 The mechanism of Amifostine (WR-2721) mediated radioprotection is poorly

87 rpose of this study was to determine whether amifostine (WR-2721) prevents or ameliorates clinically

88 trated lower swallowing dysfunction AUC with amifostine (z test P = .025).